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THE systemic  inflammatory  response  syndrome
(SIRS) is an inflammatory process seen in association
with  a  large  number  of  clinical  infective  and  non-
infective conditions.
The aim of this study was to investigate the role of
anti-inflammatory  cytokines  such  as  interleukin–4
(IL–4),  interleukin–10  (IL–10),  and  transforming
growth factor-beta (TGF-beta). Serum levels of IL–4,
IL–10 and TGF-b were determined in 45 patients with
SIRS:  38  patients  had  SIRS  of  infectious  origin,
whereas  seven  patients  had  non-infectious  SIRS.
Twenty healthy subjects were used as controls.
Serum levels of IL–4, IL–10 and TGF-b were deter-
mined  by  an  immunoenzyme  assay.  A  significant
increase of IL–4 was observed in these patients at the
time of diagnosis and 5 days later. In contrast, serum
levels  of  IL–10  were  not  increased  at  the  time  of
diagnosis, but a slight decrease was noted after 5 days.
Serum levels of TGF-b were not increased at time of
diagnosis, and a slight increase was observed after 5
days. Serum levels of IL–4 were significantly higher in
patients with infectious SIRS at the time of diagnosis,
whereas no significant difference between infectious
and non-infectious SIRS was noted for serum levels of
IL–10 and TGF-b at the time of diagnosis and 5 days
later.
During SIRS, serum levels of IL–4 were significantly
increased with a significant correlation between IL–4
and  mortality,  and  only  levels  of  IL–4  were  sig-
nificantly increased in the SIRS caused by infectious
stimuli.
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Introduction
The systemic inflammatory response syndrome (SIRS)
is an inflammatory process seen in association with a
number of clinical infective and non-infective condi-
tions.1 Besides  the  infectious  insults  caused  by
viruses, protozoa and bacteria that may cause SIRS,
non-infectious causes may include pancreatitis, multi-
ple  trauma,  ischaemia,  haemorrhagic  shock  and
immune-mediated  organ  injury.1 In  response  to  an
infectious or non-infectious stimulus, the local envi-
ronment  produces  cytokines  which  are  primarily
intended  to  evoke  an  inflammatory  response,  and
successively  small  quantities  of  inflammatory  cyto-
kines  are  released  into  the  circulation  to  enhance
local response.2 Several agents have been studied for
their  role  as  mediators of  sepsis  and  septic  shock,
including  bacterial  toxins,  cytokines  and  nitric
oxide.3–5
Acute-phase response is initiated by tumour necro-
sis factor (TNF), Il–1, and the IL–8 family, which are
grouped together and called proinflammatory cyto-
kines.6 Successively,  acute-phase  response  is  con-
trolled by  a simultaneous  decrease in  proinflamma-
tory  mediators  and  release  of  endogenous
antagonists. It  is well  known  that IL–4,  IL–10  and
transforming growth factor b (TGF-b) are considered
anti-inflammatory  cytokines  because,  when  admin-
istered  to  animals  with  infection  or  inflammation,
they reduce the severity of disease and reduce the
production of IL–1 and TNF.7
In this study we determined serum levels of anti-
inflammatory  cytokines  IL–4,  IL–10  and TGF-b in
patients with infectious and non-infectious SIRS, to
evaluate whether an anti-inflammatory cytokine pro-
file is associated with an adverse outcome.
Materials and methods
Subjects enrolled in this study were patients admitted
to the Division of Infectious Diseases, General Hospi-
tal, Bergamo, and Divisions of Medicine, Critical Care
Unit  and  Surgical  Division  of  San  Giovanni  di  Dio
Hospital, Florence. We evaluated 45  patients (mean
age: 53.9 ± 21.0 years; 26 male and 19 female) who
were  negative  for  HIV–1  infection,  and  who  met
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age: 52.5 ± 21.5 years) had infective SIRS, caused in
seven  patients  by  gram-positive  infection,  in  six
patients by gram-negative infection, in four by poly-
microbial infection, in two patients by Plasmodium
falciparum infection, in one patient by Mycobacte-
rium tuberculosis infection, in one patient by Myco-
plasma  pneumoniae infection,  in  one  patient  by
Pneumocystis  carinii infection,  and  in  16  patients
the aetiology was unknown. According to the clinical
diagnosis, 10 patients had intra-abdominal infections,
four  had  acute  endocarditis,  four  patients  suffered
from  urinary  tract  infection,  four  had  pneumonia,
three patients had acute enteritis, and 13 patients had
other infections.
Blood  samples  were  collected  at  the  time  of
diagnosis  of  SIRS,  and  5  days  later.  Serum  was
prepared by centrifugation at 1600 ´ g for 10min, and
stored at –75°C. The concentration of IL–4, IL–10 and
TGF-b was measured by using the ELISA technique (R
and D Systems, Minneapolis, MN, USA). The sensitivity
of ELISA kits to IL–4 and and IL–10 was equal to or
less than 5pg/mL in all cases, whereas the sensitivity
to TGF-b was equal to or less than 7pg/mL.
Data are expressed as mean and standard deviation,
and were compared using the non-parametric Mann-
Whitney  U  test.  Statistical  analysis  was  performed
with the significance level set at p < 0.05.
Results
Serum  levels of IL–4, IL–10 and TGF-b were deter-
mined  in  patients with  infectious  or  non-infectious
SIRS. In addition, serum levels of IL–4, IL–10 and TGF-
b were determined in 25 healthy control subjects (IL–
4: 3.2 ± 1.2pg/mL; IL–10: 1.1 ± 2.3pg/mL; TGF-b: 4.1
± 1.9pg/mL). Serum levels of IL–4, IL–10 and TGF-b
were determined in patients with infectious and non-
infectious SIRS at the time of  diagnosis and 5 days
later. A significant increase in serum levels of IL–4 was
observed  in  patients  with  SIRS  at  the  time  of
diagnosis,  whereas  Il–4  levels  did  not  significantly
change 5 days later (Table 1).
Furthermore,  serum  levels  of  IL–4  were  signifi-
cantly higher in patients with infectious SIRS than in
those with non-infectious SIRS at the time of diagnosis
(Table 1, set A), and 5 days later (Table 1, set B). In
contrast, no significant difference between infectious
and non-infectious SIRS was observed for serum levels
of IL–10 at the time of diagnosis (Table 1, set A), and
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Table 1. Serum levels of IL–4, IL–10 and TGF-b in patients with SIRS at the time of diagnosis (set
A), and five days later (set B)
Set A
Time IL–4 (pg/mL) IL–10 (pg/mL) TGF-b (pg/mL)
Infectious and non-infectious SIRS 1170.4 ± 943.1* 19.3 ± 46.2 36.1 ± 82.7
Infectious SIRS 1243.2 ± 916.7+ 21.6 ± 50.1 45.4 ± 90.6
Non-infectious SIRS 18.3 ± 2.0 16.1 ± 27.9 ND
* p < 0.0001 in comparison  with the controls;  + p = 0.001 in comparison  with infectious  SIRS; ND = not
detectable.
Set B
Time IL–4 (pg/mL) IL–10 (pg/mL) TGF-b (pg/mL)
Infectious and non-infectious SIRS 1050.3 ± 917.2 * 11.1 ± 28.4 47.9 ± 135.5
Infectious SIRS 1193.9 ± 876.5+ 11.5 ± 30.6 55.1 ± 148.3
Non-infectious SIRS 18.4 ± 1.3 5.1 ± 11.5 23.0 ± 51.5
* p < 0.0001 in comparison with the controls; + p = 0.002 in comparison with patients with non-infectious
SIRS.
Table 2. Serum levels of IL–4, IL–10 and TGF- b in survived or not-survived patients with SIRS at the time of diagnosis and five
days later
Patient groups with SIRS IL–4 (pg/mL) 0 day 5 days IL–10 (pg/mL) 0 day 5 days TGF-b (pg/mL) 0 day 5 days
Survivors (n 34) 935.6 ± 932.6 876.3 ± 897.0 23.8 ± 52.8 10.7 ± 30.9 43.2 ± 84.8 58.9 ± 152.8
Non-survivors (n 9) 1560.2 ± 872.6 1749.6 ± 613.2* ND 10.1 ± 15.9 33.6 ± 100.9 ND
* p = 0.041 when compared with the survivors; ND = not detectable.5 days later (Table 1, set B). In addition, serum levels
of  TGF-b were  not  significantly  different  between
patients with infectious SIRS and non-infectious SIRS
either at the time of diagnosis or 5 days later (Table 1,
set A and B).
Table 2 shows serum levels of IL–4, IL–10 and TGF-
b in survivor and non-survivor patients with SIRS at
the time of diagnosis and 5 days later, respectively. As
can be seen in Table 2, we did not find a significant
correlation between serum levels of IL–4, IL–10 and
TGF-b and risk of death in patients with SIRS at the
time of diagnosis. In contrast, IL–4 was significantly
associated  with  a  fatal  outcome  in  patients  with
SIRS.
Discussion
The results of this study show that response of anti-
inflammatory  cytokines  Il–10  and  TGF-b was  not
significantly increased in early and late stages of SIRS,
whereas high circulating levels of IL–4 were found in
early  and  late  stages  of  SIRS,  with  a  significant
correlation between IL–4 and mortality. In addition,
only levels of IL–4 were significantly increased in SIRS
caused  by  infectious  stimuli. The  pro-inflammatory
state of the acute phase response to infectious or non-
infectious  stimuli  also  initiates  anti-inflammatory
activity involving mediators such as IL–4, IL–10, IL–
11, TGF-b and IL-ra.8 Eventually, they should stimulate
a compensatory systemic anti-inflammatory response
to downregulate the pro-inflammatory response.9 In
particular,  IL–4  is  able  to  downregulate  human
alveolar  macrophages  and  peripheral  blood  mono-
cytes, stimulated by bacterial endotoxin, to produce
IL–1a and  IL–1b and TNF-a.10 More  recently,  van
Dissel et al.11 have shown that febrile patients with
early and advanced stages of SIRS had a fatal outcome
with a high ratio of IL–10 to TNF-a. These findings
shed new light on the debate concerning the efficacy
and safety of pro-inflammatory cytokine inhibition in
the management of sepsis.
By  blocking the action of  pro-inflammatory cyto-
kines, the circulating cytokine profile may be forced
into anti-inflammatory cytokine activation that results
in  exacerbation  of  systemic  disease  and  adverse
outcome  in  febrile  patients. The  mechanisms  that
determine the  amount  and  balance  of  various  pro-
inflammatory  and  anti-inflammatory  cytokines  are
still largely unknown. The pro- and anti-inflammatory
mechanisms  are  often  dysregulated by  several  host
and microbial factors, which determine the pattern
and  magnitude  of  the  human  cytokine  response
involved in infection.
In conclusion, compensatory systemic anti-inflam-
matory  response  which  downregulates  the  pro-
inflammatory  response  has  not  been  fully  clarified
yet,  and  the  possible  therapeutic  activity  of  anti-
inflammatory cytokines is not supported by current
experimental and clinical studies.
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